All semaglutide articles
-
OpinionBeing wrong is almost inevitable
On the tightrope of expressing your opinion, you always risk looking a fool
-
OpinionGLP-1 drugs could be more than a win–win for weight loss
Semaglutide and tirzepatide are changing lives, and could change our attitudes
-
FeatureThe GLP-1 weight loss revolution
Glucagon-like peptide-1 agonist drugs, such as semaglutide, could save countless lives at risk due to diabetes and obesity. Rachel Brazil looks at the difficulties in making the peptides themselves, and what’s coming next
-
NewsWeight-loss drugmakers bet billions on boosting supplies
Eli Lilly and Novo Nordisk invest to expand in-house manufacturing of GLP-1 drugs
-
BusinessNovo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
OpinionCompounding problems
Regulating the line between a vital service and grey-market profiteering is a mess
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments